Drugmakers Hit Pause on UK as Frustration with Government Mounts

A wave of frustration with UK government policy has led major drugmakers to hit the pause button on billions of pounds worth of investment. Companies like Sanofi, MSD, and Eli Lilly are scaling back or canceling UK projects, citing a lack of a clear and competitive strategy from ministers for the life sciences sector.
The situation was starkly outlined by Sanofi’s UK chief, who stated his company has halted any substantial new investment pending “tangible progress” from the government. This comes as the firm revealed a 50% cut in its UK clinical trials, a direct blow to the country’s research ecosystem.
The core of the frustration lies in what the industry sees as a dysfunctional and unsupportive policy environment. A “battle” between the health department and the Treasury is reportedly stalling progress, leaving critical issues like low medicine spending and outdated pricing rules unaddressed. This has created a climate of uncertainty that is toxic to long-term investment.
The consequences of this impasse are now clear, with MSD’s £1bn research center abandoned and Eli Lilly’s lab on hold. The pharmaceutical sector is effectively on an investment strike, waiting for a “proper plan” that demonstrates the government is serious about making the UK a competitive place to do business again.